• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Double Bond Pharmaceutical

0.13 SEK

-3.61 %

Less than 1K followers

DBP B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.61 %
-1.84 %
+20.81 %
+12.18 %
-43.19 %
+9.10 %
-68.79 %
-89.59 %
-95.42 %

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.

Read more
Market cap
29.75M SEK
Turnover
70.8K SEK
Revenue
84.22K
EBIT %
-2,006.39 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release5/25/2026, 12:45 PM

DBP: Double Bond Pharmaceutical submits abstract with final RWE data for Temodex to the SNO Meeting in Philadelphia

Double Bond Pharmaceutical
Press release5/6/2026, 11:04 AM

DBP: Double Bond Pharmaceutical's Abstract on Temodex Accepted for Presentation at EANS2026

Double Bond Pharmaceutical
Regulatory press release4/28/2026, 4:00 PM

DBP: Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed

Double Bond Pharmaceutical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/26/2026, 6:30 AM

DBP: Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex

Double Bond Pharmaceutical
Regulatory press release2/19/2026, 5:03 PM

DBP: Double Bond Pharmaceutical Reports Preliminary Survival Data from Large-Scale Retrospective Study of Temodex

Double Bond Pharmaceutical
Regulatory press release2/12/2026, 5:00 PM

DBP: Double Bond Pharmaceutical AB Signs Strategic Agreement for Landmark Clinical Study of Temodex® Based on Latest WHO Standards

Double Bond Pharmaceutical
Press release6/24/2025, 6:00 AM

DBP: Double Bond Pharmaceutical Re-engages Global CRO Allucent to Accelerate Phase 1 Clinical Trial for Glioblastoma Candidate SI-053

Double Bond Pharmaceutical
Press release6/17/2025, 8:59 AM

DBP: Double Bond Pharmaceutical International AB (publ) Qualifies New Swedish EU-GMP-Approved Supplier for Key Component of SI-053

Double Bond Pharmaceutical